BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38279425)

  • 41. Germline MLH1 Mutations Are Frequently Identified in Lynch Syndrome Patients With Colorectal and Endometrial Carcinoma Demonstrating Isolated Loss of PMS2 Immunohistochemical Expression.
    Dudley B; Brand RE; Thull D; Bahary N; Nikiforova MN; Pai RK
    Am J Surg Pathol; 2015 Aug; 39(8):1114-20. PubMed ID: 25871621
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lynch syndrome screening should be considered for all patients with newly diagnosed endometrial cancer.
    Mills AM; Liou S; Ford JM; Berek JS; Pai RK; Longacre TA
    Am J Surg Pathol; 2014 Nov; 38(11):1501-9. PubMed ID: 25229768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. High homogeneity of mismatch repair deficiency in advanced prostate cancer.
    Fraune C; Simon R; Höflmayer D; Möller K; Dum D; Büscheck F; Hube-Magg C; Makrypidi-Fraune G; Kluth M; Hinsch A; Burandt E; Clauditz TS; Wilczak W; Sauter G; Steurer S
    Virchows Arch; 2020 May; 476(5):745-752. PubMed ID: 31811435
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma.
    Arabi H; Guan H; Kumar S; Cote M; Bandyopadhyay S; Bryant C; Shah J; Abdul-Karim FW; Munkarah AR; Ali-Fehmi R
    Gynecol Oncol; 2009 May; 113(2):153-8. PubMed ID: 19275958
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Immunohistochemical null-phenotype for mismatch repair proteins in colonic carcinoma associated with concurrent MLH1 hypermethylation and MSH2 somatic mutations.
    Wang T; Stadler ZK; Zhang L; Weiser MR; Basturk O; Hechtman JF; Vakiani E; Saltz LB; Klimstra DS; Shia J
    Fam Cancer; 2018 Apr; 17(2):225-228. PubMed ID: 28819720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical Expression Pattern of MLH1, MSH2, MSH6, and PMS2 in Tumor Specimen of Iranian Gastric Carcinoma Patients.
    Salari S; Ghadyani M; Karimi M; Mortezazadeh M; Vahedifard F
    J Gastrointest Cancer; 2022 Mar; 53(1):192-196. PubMed ID: 33411254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Chapel DB; Yamada SD; Cowan M; Lastra RR
    Gynecol Oncol; 2018 Jun; 149(3):570-574. PubMed ID: 29656794
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular subtype diagnosis of endometrial carcinoma: comparison of the next-generation sequencing panel and Proactive Molecular Risk Classifier for Endometrial Cancer classifier.
    Huvila J; Orte K; Vainio P; Mettälä T; Joutsiniemi T; Hietanen S
    Hum Pathol; 2021 May; 111():98-109. PubMed ID: 33662372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
    Jin W; Wang LQ; Liu Y; Liu AJ
    Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
    [No Abstract]   [Full Text] [Related]  

  • 50. Diagnostic Accuracy of Immunohistochemistry for Mismatch Repair Proteins as Surrogate of Microsatellite Instability Molecular Testing in Endometrial Cancer.
    Raffone A; Travaglino A; Cerbone M; Gencarelli A; Mollo A; Insabato L; Zullo F
    Pathol Oncol Res; 2020 Jul; 26(3):1417-1427. PubMed ID: 32377987
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mismatch repair genes expression defects & association with clinicopathological characteristics in colorectal carcinoma.
    Kaur G; Masoud A; Raihan N; Radzi M; Khamizar W; Kam LS
    Indian J Med Res; 2011 Aug; 134(2):186-92. PubMed ID: 21911971
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability.
    Much M; Buza N; Hui P
    Hum Pathol; 2014 Mar; 45(3):549-55. PubMed ID: 24444463
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of Methods for Testing Mismatch Repair Status in Endometrial Cancer.
    Mendiola M; Heredia-Soto V; Ruz-Caracuel I; Baillo A; Ramon-Patino JL; Escudero FJ; Miguel M; Pelaez-Garcia A; Hernandez A; Feliu J; Hardisson D; Redondo A
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833916
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Novel Biocartis Idylla™ cartridge-based assay for detection of microsatellite instability in colorectal cancer tissues.
    Mindiola-RomeroMD AE; GreenBS DC; Al-TurkmaniPhD MR; GodwinBS KN; MackayBS AC; TafeMD LJ; RenMD B; TsongalisPhD GJ
    Exp Mol Pathol; 2020 Oct; 116():104519. PubMed ID: 32822722
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
    Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
    Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors.
    Xicola RM; Llor X; Pons E; Castells A; Alenda C; Piñol V; Andreu M; Castellví-Bel S; Payá A; Jover R; Bessa X; Girós A; Duque JM; Nicolás-Pérez D; Garcia AM; Rigau J; Gassull MA;
    J Natl Cancer Inst; 2007 Feb; 99(3):244-52. PubMed ID: 17284719
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer.
    Haron NH; Mohamad Hanif EA; Abdul Manaf MR; Yaakub JA; Harun R; Mohamed R; Mohamed Rose I
    Asian Pac J Cancer Prev; 2019 Feb; 20(2):509-517. PubMed ID: 30803214
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lessons learnt from implementation of a Lynch syndrome screening program for patients with gynaecological malignancy.
    Najdawi F; Crook A; Maidens J; McEvoy C; Fellowes A; Pickett J; Ho M; Nevell D; McIlroy K; Sheen A; Sioson L; Ahadi M; Turchini J; Clarkson A; Hogg R; Valmadre S; Gard G; Dooley SJ; Scott RJ; Fox SB; Field M; Gill AJ
    Pathology; 2017 Aug; 49(5):457-464. PubMed ID: 28669579
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Isolated loss of PMS2 expression in colorectal cancers: frequency, patient age, and familial aggregation.
    Gill S; Lindor NM; Burgart LJ; Smalley R; Leontovich O; French AJ; Goldberg RM; Sargent DJ; Jass JR; Hopper JL; Jenkins MA; Young J; Barker MA; Walsh MD; Ruszkiewicz AR; Thibodeau SN
    Clin Cancer Res; 2005 Sep; 11(18):6466-71. PubMed ID: 16166421
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic values of detecting MSI phenotypes in colorectal carcinoma by immunohistochemical method compared to molecular investigation.
    Trabelsi M; Farah F; Blel A; Jaafoura MH; Kharrat M; Rammeh S
    Tunis Med; 2017 Dec; 95(12):229-236. PubMed ID: 29878286
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.